Publication:
Pregabalin inhibits proinflammatory cytokine release in patients with fibromyalgia syndrome

dc.contributor.buuauthorEllergezen, Pınar
dc.contributor.buuauthorALP, ALEV
dc.contributor.buuauthorELLERGEZEN, PINAR
dc.contributor.buuauthorÇAVUN, SİNAN
dc.contributor.buuauthorÇavun, Sinan
dc.contributor.buuauthorÇelebi, Melih
dc.contributor.buuauthorÇELEBİ, MELİH
dc.contributor.buuauthorMacunluoğlu, Aslı Ceren
dc.contributor.departmentBursa Uludağ Üniversitesi/Tıp Fakültesi/Farmakoloji Anabilim Dalı.
dc.contributor.departmentBursa Uludağ Üniversitesi/Tıp Fakültesi/Biyoistatistik Anabilim Dalı.
dc.contributor.departmentBursa Uludağ Üniversitesi/Tıp Fakültesi/Fizik Tedavi ve Rehabilitasyon Anabilim Dalı.
dc.contributor.orcid0000-0002-6802-5998
dc.contributor.researcheridAAC-9702-2019
dc.contributor.researcheridJFJ-7690-2023
dc.date.accessioned2024-09-27T05:56:57Z
dc.date.available2024-09-27T05:56:57Z
dc.date.issued2023-06-01
dc.description.abstractObjectives: The main goal of the study was to investigate how pregabalin (PGB) affects proinflammatory cytokine release in patients with fibromyalgia syndrome (FMS).Patients and methods: This experimental research study was conducted with 85 female participants (mean age: 49.6 & PLUSMN;10.1 years; range, 30 to 73 years) between April 2020 and November 2020. Of the participants, 30 were FMS patients using PGB 150 mg/day for at least three months, 30 were FMS patients not using PGB, and 25 were healthy individuals. The detection of FMS was carried out according to the 2010 American College of Rheumatology diagnostic criteria. Levels of proinflammatory cytokines (interleukin [IL]-2, IL-6, IL-12, IL-17, interferon-gamma, and tumor necrosis factor-alpha) were measured by enzyme-linked immunosorbent assay.Results: Serum concentrations of proinflammatory cytokines were remarkably decreased in FMS patients using PGB (p<0.001) and were higher in patients with FMS not using PGB than in healthy subjects (p<0.001). The highest values of proinflammatory cytokines were found in the group of FMS patients not using PGB (p<0.001).Conclusion:These results indicate that PGB inhibits the release of proinflammatory cytokines, suggesting that it can be used as an anti-inflammatory agent in inflammatory cases.
dc.identifier.doi10.46497/ArchRheumatol.2023.9517
dc.identifier.endpage314
dc.identifier.issue2
dc.identifier.startpage307
dc.identifier.urihttps://doi.org/10.46497/ArchRheumatol.2023.9517
dc.identifier.urihttps://hdl.handle.net/11452/45360
dc.identifier.volume38
dc.identifier.wos001012605900016
dc.indexed.wosWOS.SCI
dc.language.isoen
dc.publisherTurkish League Against Rheumatism
dc.relation.journalArchives Of Rheumatology
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.subjectInflammatory cytokines
dc.subjectHypernociception
dc.subjectFamily
dc.subjectIl-12
dc.subjectPain
dc.subjectCytokines
dc.subjectFibromyalgia
dc.subjectImmunity
dc.subjectInflammation
dc.subjectPregabalin
dc.subjectScience & technology
dc.subjectLife sciences & biomedicine
dc.subjectRheumatology
dc.titlePregabalin inhibits proinflammatory cytokine release in patients with fibromyalgia syndrome
dc.typeArticle
dspace.entity.typePublication
relation.isAuthorOfPublication3f7cebd6-213b-467b-9f61-e4145ad76759
relation.isAuthorOfPublication66fd26fc-d84c-4d33-93de-4d1b17d6dae9
relation.isAuthorOfPublication9da61b72-b58e-462b-adbe-334ea91b6f78
relation.isAuthorOfPublication.latestForDiscovery3f7cebd6-213b-467b-9f61-e4145ad76759

Files

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
Ellergezen_vd_2023.pdf
Size:
198.04 KB
Format:
Adobe Portable Document Format

Collections